This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Queen's University directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.
Blood advances · 2026
Validating Restricted Mean Survival Time Estimates From Reconstructed Kaplan-Meier Data Against Original Trial Individual Patient Data From Trials Conducted by the Canadian Cancer Trials Group.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2022
The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group
Current Oncology · 2021
Latest funding
- $1,197,227
RATIONAL (Role of Antibiotic Therapy or Immunoglobulin On iNfection in hAematoLogy) Platform Trial: An RCT of continuing immunoglobulin therapy, or stopping with or without prophylactic antibiotics, on infection rate in patients with acquired hypogammaglobulinemia secondary to haematological malignancies
CIHR · 2024 · Co-investigator
- $3,056,172
A Phase III Non-Inferiority Randomized Controlled Trial (RCT) of Fixed-Duration Daratumumab Versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma
CIHR · 2023 · Nominated PI
- $3,056,176
The TACtful Trial: A first-in-human multi-centre trial of BCMA specific T-cell antigen coupler infusion, generated from cryopreserved G-CSF-mobilized peripheral blood, in patients with relapsed and refractory multiple myeloma.
CIHR · 2023 · Nominated PI
6 publications.
Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.
Gong IY, Kuruvilla J, Prica A, Olney H, Fraser G, Buckstein R, Skrabek P, Keating MM, Hay A, Shepherd L, Chen BE, Crump M
Validating Restricted Mean Survival Time Estimates From Reconstructed Kaplan-Meier Data Against Original Trial Individual Patient Data From Trials Conducted by the Canadian Cancer Trials Group.
Everest L, Blommaert S, Tu D, Pater JL, Hay A, Cheung MC, Chan KKW
The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group
Chan KKW, Cheung MC, Regier DA, Hay A, Louie AV, Cheung WY, Tarride J-E, Udayakumar S, Mittmann N
Minimization of resource utilization data collected within cost-effectiveness analyses conducted alongside Canadian Cancer Trials Group phase III trials.
Cheung MC, Chan KK, Golden S, Hay A, Pater J, Prica A, Chen BE, Leighl N, Mittmann N
The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL
Assouline S, Li S, Gisselbrecht C, Fogarty P, Hay A, van den Neste E, Shepherd LE, Schmitz N, Baetz T, Keating A
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C
RATIONAL (Role of Antibiotic Therapy or Immunoglobulin On iNfection in hAematoLogy) Platform Trial: An RCT of continuing immunoglobulin therapy, or stopping with or without prophylactic antibiotics, on infection rate in patients with acquired hypogammaglobulinemia secondary to haematological malignancies
Principal investigators: Callum, Jeannie L; Reiman, Tony
Keywords: Adaptive Platform Trial; Antibiotic Therapy; Hematologic Malignancies; Hypogammaglobulinemia; Immunoglobulin; Infections
A Phase III Non-Inferiority Randomized Controlled Trial (RCT) of Fixed-Duration Daratumumab Versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma
Principal investigators: Hay, Annette; Mian, Hira
Keywords: De-Escalation; Economic Analysis; Multiple Myeloma; Quality Of Life; Randomized Phase Iii Trial
The TACtful Trial: A first-in-human multi-centre trial of BCMA specific T-cell antigen coupler infusion, generated from cryopreserved G-CSF-mobilized peripheral blood, in patients with relapsed and refractory multiple myeloma.
Principal investigators: Hay, Annette; Bramson, Jonathan L; Delisle, Jean-Sébastien; Leblanc, Richard; Quizi, Jennifer L
Keywords: Biomanufacturing; Cancer; Cell Therapy; Clinical Trial; First-In-Human; Immunotherapy; Multiple Myeloma; Relapsed And Refractory; Synthetic Androgen Receptor
Personalized Genetic Drug Technologies and Medical Economies in Canada: Moral Experiment or Curative Renaissance?
Principal investigators: Bell, Jennifer A.H.
Keywords: bioethics; public deliberation; patient and caregiver engagement; qualitative methods; critical ethnography; personalized medicine
Personalized Genetic Drug Technologies and Medical Economies in Canada: Moral Experiment or Curative Renaissance?
Principal investigators: Bell, Jennifer A.H.
Keywords: bioethics; public deliberation; patient and caregiver engagement; qualitative methods; critical ethnography; personalized medicine
Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
Principal investigators: Hay, Annette; Cheung, Matthew C
Keywords: Chronic Lymphocytic Leukemia; Economics; Non-Inferiority; Quality Of Life; Randomized Controlled Trial; Toxicity
Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
Principal investigators: Hay, Annette; Cheung, Matthew C
Keywords: Chronic Lymphocytic Leukemia; De-Escalation; Non-Inferiority; Randomized Controlled Trial; Toxicity
Canadian Cell Therapies Workshop 2019
Principal investigators: Hay, Annette
Keywords: Cancer; Car-T Cells; Cell Manufacturing; Cellular Therapy; Planning Meeting
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Armand Keating and John Kuruvilla: 14 shared papers
- Ralph Meyer and John Kuruvilla: 5 shared papers
- Jean-Eric Tarride and Nicole Mittmann: 2 shared papers
- Ralph Meyer and Nicole Mittmann: 2 shared papers
- Annette Hay and Nicole Mittmann: 2 shared papers
- Jean-Eric Tarride and Annette Hay: 1 shared paper
- Ralph Meyer and Armand Keating: 1 shared paper
- Ralph Meyer and Annette Hay: 1 shared paper
- Armand Keating and Annette Hay: 1 shared paper
- Annette Hay and John Kuruvilla: 1 shared paper
- Mechanical Engineering
- Health Research Methods, Evidence, and Impact
- Oncology
- Other
Co-authors at Queen's University, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Nicole Mittmann
Faculty
2 shared papers, latest 2021
John Kuruvilla
Faculty
1 shared papers, latest 2026
Jean-Eric Tarride
Health Research Methods, Evidence, and Impact
1 shared papers, latest 2021
Ralph Meyer
Oncology
1 shared papers, latest 2020
Armand Keating
Mechanical Engineering
1 shared papers, latest 2020
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.